All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
On October 1, 2021, brexucabtagene autoleucel (brexu-cel) became the first chimeric antigen receptor (CAR) T-cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with acute lymphoblastic leukemia (ALL). Brexu-cel is now indicated for patients aged ≥18 years with relapsed or refractory B-cell precursor ALL.
A supplemental biologics license application was submitted for the CD19-directed CAR T-cell therapy in April 2021 based on the encouraging responses observed in the ZUMA-3 trial (NCT02614066). The ongoing phase I/II study is evaluating the safety and efficacy of brexu-cel in adult patients with relapsed or refractory ALL following standard systemic therapy or hematopoietic stem cell transplantation. At a median follow-up of 12.3 months, complete remission (CR)/CR with incomplete hematologic recovery (CRi) was observed in 65% of evaluable patients (n = 54). The median duration of CR was expected to surpass 12 months in over half of patients. Median duration of remission was 13.6 months across efficacy-evaluable patients, and cytokine release syndrome and neurologic events were controlled in patients who received the target dose (n = 78). The pivotal phase II results of the ZUMA-3 trial were recently published in Lancet.
Relapse rates in adult ALL are high and overall survival remains suboptimal; the approval of brexu-cel may go some way to address the unmet need in this patient population. Brexu-cel is also being evaluated for the treatment of pediatric patients with ALL.
BusinessWire. U.S. FDA approves Kite’s Tecartus® as the first and only Car T for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. https://www.businesswire.com/news/home/20211001005719/en/U.S.-FDA-Approves-Kite%E2%80%99s-Tecartus%C2%AE-as-the-First-and-Only-Car-T-for-Adults-With-Relapsed-or-Refractory-B-cell-Acute-Lymphoblastic-Leukemia. Published Oct 1, 2021. Accessed Oct 4, 2021.
Supplemental biologics license application submitted for brexucabtagene autoleucel for use in R/R B-cell ALL
Relapsed or refractory (R/R) acute lymphoblastic lymphoma (ALL) is associated with poor prognosis and short overall survival. B-cell ALL is...
Is the anti-CD19 CAR-T brexu-cel safe and effective in B-ALL?
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Bijal Shah, Moffitt Cancer Center, Tampa, US. We asked, Is the anti-CD19 CAR-T brexu-cel (formerly KTE-X19) safe and effective...
Subscribe to get the best content related to ALL delivered to your inbox